267 results
P
patients with de novo IAs
I/C
systematic review and meta-analysis of existing de novo IA cohorts, initial IAs in the middle cerebral artery
O
de novo IAs
P
idosos
I/C
prevenção de quedas, não-prevenção
O
prevenção de quedas
P
patients with allergic rhinitis
I/C
oral H, placebo
O
total symptom score reduction, nasal congestion score reduction, rhinorrhea score reduction, ocular symptom score reduction, nasal itching score reduction, sneezing score reduction
P
NAFLD, elderly, pre-LT type II diabetes mellitus
I/C
de novo PTMS, other liver diseases
O
cardiovascular disease events
P
541 participants
I/C
periodontal treatment, conventional systemic H. pylori eradication therapy alone
O
gastric H. pylori eradication rates
P
pacientes con COVID-19
I/C
inhibidores de la enzima convertidora de angiotensina, bloqueadores del receptor de angiotensina II, placebo o ningún tratamiento
O
efectos sobre la COVID-19
P
animals
I/C
hypothermic machine perfusion, subnormothermic machine perfusion, warm ischemia without cold storage, normothermic machine perfusion, static cold storage (< 12 h), warm ischemia without cold storage, normothermic machine perfusion, static cold storage (< 12 h), static cold storage (≥ 12 h)
O
ATP content, respiratory activity of mitochondrial complexes, cytochrome c release, aspartate aminotransferase (ALT) release
P
working-age (≥15 years) workers in the formal and informal economy
I/C
exposure to long working hours (41-48, 49-54 and ≥55 h/week), exposure to standard working hours (35-40 h/week)
O
depression (prevalence, incidence and mortality)
P
Helicobacter pylori (H. pylori) positive peptic ulcer disease (PUD)
I/C
Chinese herbal formulae, conventional triple therapy (CON)
O
eradication rate, clinical efficiency, recurrence rate
P
adult individuals
I/C
low-sodium salt substitute (LSSS), no LSSS
O
lower 24-h urinary sodium excretion